Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.
2.

Emotional development in the context of mother-child relationships.

Hollenstein T, Tighe AB, Lougheed JP.

Curr Opin Psychol. 2017 Oct;17:140-144. doi: 10.1016/j.copsyc.2017.07.010. Epub 2017 Jul 18. Review.

PMID:
28950960
3.

Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers.

Bennett A, Sloss O, Topham C, Nelson L, Tighe A, Taylor SS.

Open Biol. 2016 Aug;6(8). pii: 160134. doi: 10.1098/rsob.160134.

4.

Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1.

Aspinall CF, Zheleva D, Tighe A, Taylor SS.

Oncotarget. 2015 Nov 3;6(34):36472-88. doi: 10.18632/oncotarget.5507.

5.

Cenp-E inhibitor GSK923295: Novel synthetic route and use as a tool to generate aneuploidy.

Bennett A, Bechi B, Tighe A, Thompson S, Procter DJ, Taylor SS.

Oncotarget. 2015 Aug 28;6(25):20921-32.

6.

MYC Is a Major Determinant of Mitotic Cell Fate.

Topham C, Tighe A, Ly P, Bennett A, Sloss O, Nelson L, Ridgway RA, Huels D, Littler S, Schandl C, Sun Y, Bechi B, Procter DJ, Sansom OJ, Cleveland DW, Taylor SS.

Cancer Cell. 2015 Jul 13;28(1):129-40. doi: 10.1016/j.ccell.2015.06.001.

7.

Individualised cognitive functional therapy compared with a combined exercise and pain education class for patients with non-specific chronic low back pain: study protocol for a multicentre randomised controlled trial.

O'Keeffe M, Purtill H, Kennedy N, O'Sullivan P, Dankaerts W, Tighe A, Allworthy L, Dolan L, Bargary N, O'Sullivan K.

BMJ Open. 2015 Jun 1;5(6):e007156. doi: 10.1136/bmjopen-2014-007156.

8.

The NHS may be challenged, but my father's care is praiseworthy.

Tighe A.

Nurs Stand. 2015 Mar 4;29(27):33. doi: 10.7748/ns.29.27.33.s40. No abstract available.

PMID:
25736670
9.

Botulinum neurotoxins: mechanism of action.

Tighe AP, Schiavo G.

Toxicon. 2013 Jun 1;67:87-93. doi: 10.1016/j.toxicon.2012.11.011. Epub 2012 Nov 29. Review.

PMID:
23201505
10.

Multisystemic therapy for young offenders: families' experiences of therapeutic processes and outcomes.

Tighe A, Pistrang N, Casdagli L, Baruch G, Butler S.

J Fam Psychol. 2012 Apr;26(2):187-97. doi: 10.1037/a0027120. Epub 2012 Feb 13.

PMID:
22329390
11.

p31comet-mediated extraction of Mad2 from the MCC promotes efficient mitotic exit.

Westhorpe FG, Tighe A, Lara-Gonzalez P, Taylor SS.

J Cell Sci. 2011 Nov 15;124(Pt 22):3905-16. doi: 10.1242/jcs.093286. Epub 2011 Nov 18.

12.

A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury.

Fehlings MG, Theodore N, Harrop J, Maurais G, Kuntz C, Shaffrey CI, Kwon BK, Chapman J, Yee A, Tighe A, McKerracher L.

J Neurotrauma. 2011 May;28(5):787-96. doi: 10.1089/neu.2011.1765.

PMID:
21381984
13.

Bare-eye view at the nanoscale: new visual interferometric multi-indicator (VIMI).

Panagiotopoulos NT, Patsalas P, Prouskas C, Dimitrakopulos GP, Komninou P, Karakostas T, Tighe AP, Lidorikis E.

ACS Appl Mater Interfaces. 2010 Nov;2(11):3052-8. doi: 10.1021/am100532b. Epub 2010 Nov 4.

PMID:
21049957
14.

Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine.

Santaguida S, Tighe A, D'Alise AM, Taylor SS, Musacchio A.

J Cell Biol. 2010 Jul 12;190(1):73-87. doi: 10.1083/jcb.201001036.

15.

Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex.

Hewitt L, Tighe A, Santaguida S, White AM, Jones CD, Musacchio A, Green S, Taylor SS.

J Cell Biol. 2010 Jul 12;190(1):25-34. doi: 10.1083/jcb.201002133.

16.

Re-evaluating the role of Tao1 in the spindle checkpoint.

Westhorpe FG, Diez MA, Gurden MD, Tighe A, Taylor SS.

Chromosoma. 2010 Aug;119(4):371-9. doi: 10.1007/s00412-010-0261-1. Epub 2010 Feb 17.

PMID:
20162290
17.

Cdc20 is required for the post-anaphase, KEN-dependent degradation of centromere protein F.

Gurden MD, Holland AJ, van Zon W, Tighe A, Vergnolle MA, Andres DA, Spielmann HP, Malumbres M, Wolthuis RM, Cleveland DW, Taylor SS.

J Cell Sci. 2010 Feb 1;123(Pt 3):321-30. doi: 10.1242/jcs.062075. Epub 2010 Jan 5.

18.

Anatomy of the sacral nerve roots: clinical implications for neural repair.

Fehlings MG, Tighe A.

J Neurosurg Spine. 2009 Sep;11(3):253-4; discussion 254. doi: 10.3171/2009.4.SPINE00247. No abstract available.

PMID:
19769505
19.

Spinal cord injury and neural repair: focus on neuroregenerative approaches for spinal cord injury.

Baptiste DC, Tighe A, Fehlings MG.

Expert Opin Investig Drugs. 2009 May;18(5):663-73. doi: 10.1517/13543780902897623 . Review.

PMID:
19379122
20.

Gene expression profiling in anti-CD11d mAb-treated spinal cord-injured rats.

Gris P, Tighe A, Thawer S, Hemphill A, Oatway M, Weaver L, Dekaban GA, Brown A.

J Neuroimmunol. 2009 Apr 30;209(1-2):104-13. doi: 10.1016/j.jneuroim.2009.02.002. Epub 2009 Feb 27.

PMID:
19250688
21.

Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective.

Collins N, Tighe AP, Brunton SA, Kris-Etherton PM.

J Am Coll Nutr. 2008 Dec;27(6):659-66. Review.

PMID:
19155425
22.

Spinal cord injury: the promise of translational research.

Fehlings MG, Tighe A.

Neurosurg Focus. 2008;25(5):E1. doi: 10.3171/FOC.2008.25.11.E1. Review.

PMID:
18980469
23.

Dispelling the myths about omega-3 fatty acids.

Sadovsky R, Collins N, Tighe AP, Safeer RS, Morris CM, Brunton SA.

Postgrad Med. 2008 Jul;120(2):92-100. doi: 10.3810/pgm.2008.07.1796. Review.

PMID:
18654074
24.

Mps1 kinase activity restrains anaphase during an unperturbed mitosis and targets Mad2 to kinetochores.

Tighe A, Staples O, Taylor S.

J Cell Biol. 2008 Jun 16;181(6):893-901. doi: 10.1083/jcb.200712028. Epub 2008 Jun 9.

25.

n-3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects.

Jung UJ, Torrejon C, Tighe AP, Deckelbaum RJ.

Am J Clin Nutr. 2008 Jun;87(6):2003S-9S.

PMID:
18541602
26.

Patient use of dietary supplements: a clinician's perspective.

Sadovsky R, Collins N, Tighe AP, Brunton SA, Safeer R.

Curr Med Res Opin. 2008 Apr;24(4):1209-16. doi: 10.1185/030079908X280743 . Epub 2008 Mar 17. Review.

PMID:
18348745
27.

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.

Bays HE, Tighe AP, Sadovsky R, Davidson MH.

Expert Rev Cardiovasc Ther. 2008 Mar;6(3):391-409. doi: 10.1586/14779072.6.3.391. Review.

PMID:
18327998
28.

HIV services threatened by cutbacks and drug costs.

Tighe A.

Nurs Stand. 2008 Jan 9-15;22(18):33. No abstract available.

PMID:
18240803
29.

Transcriptional activation of the suppressor of cytokine signaling-3 (SOCS-3) gene via STAT3 is increased in F9 REX1 (ZFP-42) knockout teratocarcinoma stem cells relative to wild-type cells.

Xu J, Sylvester R, Tighe AP, Chen S, Gudas LJ.

J Mol Biol. 2008 Mar 14;377(1):28-46. doi: 10.1016/j.jmb.2007.12.038. Epub 2008 Jan 30.

30.

Mitochondrial targeting of adenomatous polyposis coli protein is stimulated by truncating cancer mutations: regulation of Bcl-2 and implications for cell survival.

Brocardo M, Lei Y, Tighe A, Taylor SS, Mok MT, Henderson BR.

J Biol Chem. 2008 Feb 29;283(9):5950-9. Epub 2007 Dec 26.

31.

Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives.

Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ.

Atherosclerosis. 2008 Mar;197(1):12-24. Epub 2007 Dec 26. Review.

PMID:
18160071
32.

GSK-3 inhibitors induce chromosome instability.

Tighe A, Ray-Sinha A, Staples OD, Taylor SS.

BMC Cell Biol. 2007 Aug 14;8:34.

33.

Transcriptional regulation of scar gene expression in primary astrocytes.

Gris P, Tighe A, Levin D, Sharma R, Brown A.

Glia. 2007 Aug 15;55(11):1145-55.

PMID:
17597120
34.

Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20.

Morrow CJ, Tighe A, Johnson VL, Scott MI, Ditchfield C, Taylor SS.

J Cell Sci. 2005 Aug 15;118(Pt 16):3639-52. Epub 2005 Jul 26.

35.

Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability.

Tighe A, Johnson VL, Taylor SS.

J Cell Sci. 2004 Dec 15;117(Pt 26):6339-53. Epub 2004 Nov 23.

37.
38.

Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.

Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS.

J Cell Biol. 2003 Apr 28;161(2):267-80.

39.

Development of a novel rapid assay to assess the fidelity of DNA double-strand-break repair in human tumour cells.

Collis SJ, Sangar VK, Tighe A, Roberts SA, Clarke NW, Hendry JH, Margison GP.

Nucleic Acids Res. 2002 Jan 15;30(2):E1.

40.

Aneuploid colon cancer cells have a robust spindle checkpoint.

Tighe A, Johnson VL, Albertella M, Taylor SS.

EMBO Rep. 2001 Jul;2(7):609-14. Epub 2001 Jul 3.

41.

Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.

Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP.

Nucleic Acids Res. 2001 Apr 1;29(7):1534-8.

42.
43.

Effect of caloric restriction on colonic proliferation in obese persons: implications for colon cancer prevention.

Steinbach G, Heymsfield S, Olansen NE, Tighe A, Holt PR.

Cancer Res. 1994 Mar 1;54(5):1194-7.

44.

Polymorphism at the glutathione S-transferase GSTM1 locus: a study of the frequencies of the GSTM1 A, B, A/B and null phenotypes in Nigerians.

Zhao L, Alldersea J, Fryer A, Tighe A, Ollier B, Thomson W, Jones P, Strange R.

Clin Chim Acta. 1994 Feb;225(1):85-8. No abstract available.

PMID:
8033359

Supplemental Content

Support Center